Zydus receives warning letter from USFDA for Jarod injectables manufacturing facility
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Subscribe To Our Newsletter & Stay Updated